Novamind 5 review full#
Novamind 5 review series#

Ketamine infusion for depression usually costs $400 to $800 per session, and most ketamine clinics perform a series of 6 sessions over 2 to 3 weeks.

Novamind 5 review full#

The therapy can cost anywhere from $1,600 CAD to $6,000 CAD for a full series of ketamine treatments. The main service people use ketamine clinics for is ketamine infusion therapy. In the early studies of ketamine, a substantial portion of patients would experience dramatic improvement just 4 hours after dosing. Part of the excitement about ketamine and esketamine is that this approach has the potential to improve mood and other depressive symptoms on a much shorter time scale than classic antidepressants, such as selective serotonin reuptake inhibitors. Whoever wins that race will be rewarded handomsly.Įsketamine is the S-enantiomer of ketamine, which is more potent at the N-methyl-D-aspartate (NMDA) glutamate receptor. One example in the psychedelics sector is a derivative of ketamine called esketamine that companies like Braxia ( BRAX.C), Novamind ( NM.C), and Field Trip (FTRP.C) are using in their ‘ketamine clinics’.Ĭompanies like Cybin ( CYBN.NE), Compass Pathways ( CMPS.Q) and Mindset Pharma ( MSET.C) are working on developing something similar with psilocybin. These are sometimes referred to as ‘novel compounds’. Others have either opened or partnered with clinics that provide their patients with an almost illegal drug that has nevertheless been approved by the FDA for a number of mental health issues.Īn NCE (new chemical entity) is used to describe a newly developed drug compound, as opposed to the re-use of an existing drug for a different disease, re-formulation of an existing drug, or a novel combination of existing drugs. And with so much hype in the sector, why not take a shot?įor early revenue generation, some companies have chosen to sell legal functional mushroom supplements.

And a certain subset of the mining dinosaurs laughed it off like they laughed off cannabis back around 2016.Ĭritics are right that mainstream recreational psychedelic use is in fact far away, but there are still a number of ways a psychedelics company can create value long before that event happens. I remember the stiffs at the Cannacord conference a couple of years back laughing at the idea of a psychedelics sector. Early on in the shroom boom critics had one major pain point – legalization is too far away.